Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis

AUTOR(ES)

Natividade, Natallia Barreiros de, Felix, Paulo Antonio Oldani, Lerer, Claudio

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

2017

RESUMO

Abstract The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.

Documentos Relacionados

• Guillain-Barré syndrome following zimeldine treatment.
• Treatment of the Guillain-Barré syndrome by plasma exchange.
• Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barré syndrome.
• Toxoplasma gondii-Associated Guillain-Barré Syndrome in an Immunocompetent Patient
• Hypokalaemia mimicking Guillain-Barré syndrome.